Priscilla Thomas Lopes

Priscilla Thomas Lopes

Auto-generated profile, based on publicly available information

Priscilla Thomas Lopes

Stem Cells & Development Unit, 25 rue du Dr. Roux, Institut Pasteur, 75015 Paris, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CPClaire Pujol
Claire Pujol
ALAnne Legrand
Anne Legrand
LPLivia Parodi
Livia Parodi
PTPriscilla Thomas
Priscilla Thomas
FMFanny MOCHEL
Fanny MOCHEL
GSGiovanni Stevanin
Giovanni Stevanin
Hereditary spastic paraplegias are heterogeneous neurodegenerative disorders. Understanding of their pathogenic mechanisms remains sparse, and therapeutic options are lacking. We characterized a mouse model lacking the Cyp2u1 gene, loss of which is known to be involved in a complex form of these diseases in humans. We showed that this model partially recapitulated the clinical and biochemical phenotypes of patients. Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far. We also confirmed brain calcifications as a potential biomarker in patients. Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues.